



NE

**MEDICAL EXAMINATION REPORT (MER)**

If the examinee is suffering from an acute life threatening situation, you may be obliged to disclose the result of the medical examination to the examinee.

1. Name of the examinee	:	Mr./Mrs./Ms. <u>Bilal Abraham</u>
2. Mark of Identification	:	(Mole/Scar/any other (specify location)):
3. Age/Date of Birth	:	<u>14/01/1976</u> Gender: <u>F/M</u>
4. Photo ID Checked	:	(Passport/Election Card/PAN Card/Driving Licence/Company ID)

**PHYSICAL DETAILS:**

a. Height <u>160</u> (cms)	b. Weight <u>70</u> (Kgs)	c. Girth of Abdomen <u>92</u> (cms)
d. Pulse Rate <u>70</u> (/Min)	e. Blood Pressure:	Systolic <u>130</u> Diastolic <u>80</u>
	1 <sup>st</sup> Reading	
	2 <sup>nd</sup> Reading	

**FAMILY HISTORY:**

Relation	Age if Living	Health Status	If deceased, age at the time and cause
Father		/ NS	
Mother			
Brother(s)			
Sister(s)			

**HABITS & ADDICTIONS:** Does the examinee consume any of the following?

Tobacco in any form	Sedative	Alcohol
—	—	—

**PERSONAL HISTORY**

- a. Are you presently in good health and entirely free from any mental or Physical impairment or deformity. If No, please attach details. Y/N Y
- b. Have you undergone/been advised any surgical procedure? Y/N Y
- c. During the last 5 years have you been medically examined, received any advice or treatment or admitted to any hospital? Y/N Y
- d. Have you lost or gained weight in past 12 months? Y/N Y

**Have you ever suffered from any of the following?**

- Psychological Disorders or any kind of disorders of the Nervous System? Y/N Y
- Any disorders of Respiratory system? Y/N Y
- Any Cardiac or Circulatory Disorders? Y/N Y
- Enlarged glands or any form of Cancer/Tumour? Y/N Y
- Any Musculoskeletal disorder? Y/N Y
- Any disorder of Gastrointestinal System? Y/N Y
- Unexplained recurrent or persistent fever, and/or weight loss Y/N Y
- Have you been tested for HIV/HBsAg / HCV before? If yes attach reports Y/N Y
- Are you presently taking medication of any kind? Y/N Y

**DDRC SRL Diagnostics Private Limited**

Corp. Office: DDRC SRL Tower, G- 131, Panampilly Nagar, Ernakulam - 682 036  
Ph No. 0484-2318223, 2318222, e-mail: info@ddrcsrl.com, web: www.ddrcsrl.com

Regd. Office: 4th Floor, Prime Square, Plot No.1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (West), Mumbai – 400062.

• Any disorders of Urinary System?

Y/N

• Any disorder of the Eyes, Ears, Nose, Throat or Mouth & Skin

Y/N

**FOR FEMALE CANDIDATES ONLY**

a. Is there any history of diseases of breast/genital organs?

Y/N

d. Do you have any history of miscarriage/abortion or MTP

Y/N

b. Is there any history of abnormal PAP Smear/Mammogram/USG of Pelvis or any other tests? (If yes attach reports)

Y/N

e. For Parous Women, were there any complication during pregnancy such as gestational diabetes, hypertension etc

Y/N

c. Do you suspect any disease of Uterus, Cervix or Ovaries?

Y/N

f. Are you now pregnant? If yes, how many months?

Y/N

**CONFIDENTIAL COMMENTS FROM MEDICAL EXAMINER**

➤ Was the examinee co-operative?

Y/N

➤ Is there anything about the examinee's health, lifestyle that might affect him/her in the near future with regard to his/her job?

Y/N

➤ Are there any points on which you suggest further information be obtained?

Y/N

➤ Based on your clinical impression, please provide your suggestions and recommendations below;


..... NS .....

➤ Do you think he/she is MEDICALLY FIT or UNFIT for employment.

FIT

**MEDICAL EXAMINER'S DECLARATION**

I hereby confirm that I have examined the above individual after verification of his/her identity and the findings stated above are true and correct to the best of my knowledge.

Name & Signature of the Medical Examiner : 

Seal of Medical Examiner : 

Name & Seal of DDRC SRL Branch :

Date & Time :



14/03/2023

**DDRC SRL Diagnostics Private Limited**

Corp. Office: DDRC SRL Tower, G- 131, Panampilly Nagar, Ernakulam - 682 036  
Ph No. 0484-2318223, 2318222, e-mail: info@ddrcsrl.com, web: www.ddrcsrl.com

Regd. Office: 4th Floor, Prime Square, Plot No.1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (West), Mumbai – 400062.

Motum test not desired

Bilal

Bilal Abrehan

Mathew George  
Mathew George.

bilal.abrehan@gmail.com





**INDIAN UNION**  
**KERALA STATE**  
**DRIVING LICENCE** FORM 7



No.: 25/1569/2003      Date: 27/08/2016  
Name :BILALO ABRAHAM  
S/W/D of :Abraham C  
Address :Kiduthattil House  
          Karimakkad  
          Thrikkakara  
          Kochi 21

Date of Birth :14/01/1976  
Blood Group :  
Category :  
Non-Transport  
Transport

Valid from :19/08/2016      Valid To :13/01/2026



*Bilalo*







Patient Ref. No. 66600003704552

 CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS :

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 11/03/2023 17:18

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

**MEDIWHEEL HEALTH CHECKUP ABOVE 40(F)TMT****BLOOD UREA NITROGEN (BUN), SERUM**
 BLOOD UREA NITROGEN 12 Adult(<60 yrs) : 6 to 20 mg/dL  
 METHOD : UREASE - UV
**BUN/CREAT RATIO**

BUN/CREAT RATIO 15

**CREATININE, SERUM**CREATININE 0.80 18 - 60 yrs : 0.6 - 1.1 mg/dL  
METHOD : JAFFE KINETIC METHOD**GLUCOSE, POST-PRANDIAL, PLASMA**
 GLUCOSE, POST-PRANDIAL, PLASMA 92 Diabetes Mellitus : > or = 200. mg/dL  
 Impaired Glucose tolerance/  
 Prediabetes : 140 - 199.  
 Hypoglycemia : < 55.

METHOD : HEXOKINASE

**LIPID PROFILE, SERUM**
 CHOLESTEROL 193 Desirable : < 200 mg/dL  
 Borderline : 200-239  
 High : >or= 240

METHOD : CHOD-POD

TRIGLYCERIDES 112 Normal : < 150 mg/dL  
High : 150-199Hypertriglyceridemia : 200-499  
Very High : > 499

HDL CHOLESTEROL 53 General range : 40-60 mg/dL

METHOD : DIRECT ENZYME CLEARANCE

DIRECT LDL CHOLESTEROL 116 Optimum : < 100 mg/dL  
Above Optimum : 100-139  
Borderline High : 130-159  
High : 160-189  
Very High : >or= 190NON HDL CHOLESTEROL 140 High Desirable: Less than 130 mg/dL  
Above Desirable: 130 - 159  
Borderline High: 160 - 189  
High: 190 - 219  
Very high: > or = 220
 VERY LOW DENSITY LIPOPROTEIN 22.4 Desirable value : mg/dL  
 10 - 35


Scan to View Details

Page 2 Of 15



Scan to View Report



Patient Ref. No. 66600003704552

 CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS : MEDIWHEEL HEALTHCARE LIMITED

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 11/03/2023 17:18

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

CHOL/HDL RATIO

3.6

 3.3-4.4 Low Risk  
 4.5-7.0 Average Risk  
 7.1-11.0 Moderate Risk  
 > 11.0 High Risk

LDL/HDL RATIO

2.2

 0.5 - 3.0 Desirable/Low Risk  
 3.1 - 6.0 Borderline/Moderate Risk  
 >6.0 High Risk


Scan to View Details

Page 3 Of 15



Scan to View Report





Patient Ref. No. 66600003704552

 CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS:

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 11/03/2023 17:18

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

**Interpretation(s)**

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3) HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5) Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

**Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India**

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
<b>Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors</b>	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)



Scan to View Details

Page 4 Of 15



Scan to View Report





Patient Ref. No. 66600003704552

 CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS :

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 11/03/2023 17:18

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

\*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

**GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD**

GLYCOSYLATED HEMOGLOBIN (HBA1C) 5.2

 Normal : 4.0 - 5.6%. %  
 Non-diabetic level : < 5.7%.  
 Diabetic : >6.5%

 Glycemic control goal  
 More stringent goal : < 6.5 %.  
 General goal : < 7%.  
 Less stringent goal : < 8%.

 Glycemic targets in CKD :-  
 If eGFR > 60 : < 7%.  
 If eGFR < 60 : 7 - 8.5%.  
 < 116.0 mg/dL

MEAN PLASMA GLUCOSE 102.5

**LIVER FUNCTION TEST WITH GGT**

BILIRUBIN, TOTAL 0.70

METHOD : DIAZO METHOD

General Range : &lt; 1.1 mg/dL

BILIRUBIN, DIRECT 0.35

METHOD : DIAZO METHOD

General Range : &lt; 0.3 mg/dL

BILIRUBIN, INDIRECT 0.35

0.00 - 0.60 mg/dL

TOTAL PROTEIN 7.1

Ambulatory : 6.4 - 8.3 g/dL

ALBUMIN 4.1

Recumbant : 6 - 7.8

GLOBULIN 3.0

20-60yrs : 3.5 - 5.2 g/dL

2.0 - 4.0 g/dL

Neonates -

Pre Mature:

0.29 - 1.04

ALBUMIN/GLOBULIN RATIO 1.4

1.00 - 2.00

RATIO



Scan to View Details

Page 5 Of 15



Scan to View Report



Patient Ref. No. 666000003704552

 CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS:

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 11/03/2023 17:18

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	15	Adults : < 33	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	12	Adults : < 34	U/L
METHOD : IFCC WITHOUT PDP			
ALKALINE PHOSPHATASE	87	Adult (<60yrs) : 35 - 105	U/L
METHOD : IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	11	Adult (female) : < 40	U/L
<b>TOTAL PROTEIN, SERUM</b>			
TOTAL PROTEIN	7.1	Ambulatory : 6.4 - 8.3 Recumbant : 6 - 7.8	g/dL
METHOD : BIURET			
<b>URIC ACID, SERUM</b>			
URIC ACID	4.3	Adults : 2.4-5.7	mg/dL
METHOD : SPECTROPHOTOMETRY			
<b>ABO GROUP &amp; RH TYPE, EDTA WHOLE BLOOD</b>			
ABO GROUP		TYPE O	
METHOD : GEL CARD METHOD			
RH TYPE		POSITIVE	
<b>BLOOD COUNTS, EDTA WHOLE BLOOD</b>			
HEMOGLOBIN	13.6	12.0 - 15.0	g/dL
METHOD : NON CYANMETHHEMOGLOBIN			
RED BLOOD CELL COUNT	4.63	3.8 - 4.8	mil/ $\mu$ L
METHOD : IMPEDANCE			
WHITE BLOOD CELL COUNT	6.51	4.0 - 10.0	thou/ $\mu$ L
METHOD : IMPEDANCE			
PLATELET COUNT	247	150 - 410	thou/ $\mu$ L
METHOD : IMPEDANCE			
<b>RBC AND PLATELET INDICES</b>			
HEMATOCRIT	40.9	36 - 46	%
METHOD : CALCULATED			
MEAN CORPUSCULAR VOL	88.4	83 - 101	fL
METHOD : DERIVED FROM IMPEDANCE MEASURE			
MEAN CORPUSCULAR HGB,	29.3	27.0 - 32.0	pg
METHOD : CALCULATED			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION	33.2	31.5 - 34.5	g/dL




Scan to View Details

Page 6 Of 15



Scan to View Report





Patient Ref. No. 666000003704552

 CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS :

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 14/03/2023 08:04

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
METHOD : CALCULATED			
RED CELL DISTRIBUTION WIDTH	14.1	12.0 - 18.0	%
MENTZER INDEX	19.1		
MEAN PLATELET VOLUME	9.9	6.8 - 10.9	fL
METHOD : DERIVED FROM IMPEDANCE MEASURE			
<b>WBC DIFFERENTIAL COUNT</b>			
SEGMENTED NEUTROPHILS	50	40 - 80	%
METHOD : DHSS FLOWCYTOMETRY			
LYMPHOCYTES	37	20 - 40	%
METHOD : DHSS FLOWCYTOMETRY			
MONOCYTES	6	2 - 10	%
METHOD : DHSS FLOWCYTOMETRY			
EOSINOPHILS	7	High 1 - 6	%
METHOD : DHSS FLOWCYTOMETRY			
BASOPHILS	0	0 - 2	%
METHOD : IMPEDANCE			
ABSOLUTE NEUTROPHIL COUNT	3.26	2.0 - 7.0	thou/ $\mu$ L
METHOD : CALCULATED			
ABSOLUTE LYMPHOCYTE COUNT	2.41	1 - 3	thou/ $\mu$ L
METHOD : CALCULATED			
ABSOLUTE MONOCYTE COUNT	0.39	0.20 - 1.00	thou/ $\mu$ L
METHOD : CALCULATED			
ABSOLUTE EOSINOPHIL COUNT	0.46	0.02 - 0.50	thou/ $\mu$ L
METHOD : CALCULATED			
ABSOLUTE BASOPHIL COUNT	0.00	0.00 - 0.10	thou/ $\mu$ L
METHOD : CALCULATED			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.4		
<b>ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD</b>			
SEDIMENTATION RATE (ESR)	18	0 - 20	mm at 1 hr
METHOD : WESTEREGREN METHOD			
<b>SUGAR URINE - POST PRANDIAL</b>			
SUGAR URINE - POST PRANDIAL	NOT DETECTED	NOT DETECTED	
<b>CYTOLOGY - CS (PAP SMEAR)</b>			



Scan to View Details



Scan to View Report





Patient Ref. No. 66600003704552

**CLIENT CODE :** CA00010147 - MEDIWHEEL  
**CLIENT'S NAME AND ADDRESS :**

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in
**PATIENT NAME :** MRS. BILALO ABRAHAM**PATIENT ID :** BILAF1103764126**ACCESSION NO :** 4126WC003808 **AGE :** 47 Years **SEX :** Female**ABHA NO :****DRAWN :****RECEIVED :** 11/03/2023 11:12**REPORTED :** 14/03/2023 08:04**REFERRING DOCTOR :** DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED**CLIENT PATIENT ID :**

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

**CYTOLOGY - CS (PAP SMEAR)**  
**CYTOLOGY NO : CY/1213/2023**
**NATURE OF SPECIMEN :** Pap smear.**GROSS SPECIMEN :** 2 smears stained.**MICROSCOPY:**
 Satisfactory smear shows superficial and intermediate squamous cells, in a background of lactobacilli.  
 No atypical cells seen.
**IMPRESSION :** Negative for intraepithelial lesion or malignancy.**THYROID PANEL, SERUM**

<b>T3</b> METHOD : ELECTROCHEMILUMINESCENCE	<b>78.17</b>	<b>Low</b> 80 - 200	ng/dL
<b>T4</b> METHOD : ELECTROCHEMILUMINESCENCE	<b>6.14</b>	5.1 - 14.1	µg/dl
<b>TSH 3RD GENERATION</b> METHOD : ELECTROCHEMILUMINESCENCE	<b>3.360</b>	Non-Pregnant : 0.4-4.2 Pregnant Trimester-wise : 1st : 0.1 - 2.5 2nd : 0.2 - 3 3rd : 0.3 - 3	µIU/mL



Scan to View Details

Page 8 Of 16




Scan to View Report

CIN : U85190MH2006PTC161480

(Refer to "CONDITIONS OF REPORTING" Overleaf)





Patient Ref. No. 666000003704552

**CLIENT CODE :** CA00010147 - MEDIWHEEL  
**CLIENT'S NAME AND ADDRESS :** THUCARE LIMITED

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in
**PATIENT NAME :** MRS. BILALO ABRAHAM**PATIENT ID :** BILAF1103764126**ACCESSION NO :** 4126WC003808 **AGE :** 47 Years **SEX :** Female**ABHA NO :****DRAWN :****RECEIVED :** 11/03/2023 11:12**REPORTED :** 14/03/2023 08:04**REFERRING DOCTOR :** DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED**CLIENT PATIENT ID :**

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

**Interpretation(s)**

**Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidelines of the American Thyroid association during pregnancy and Postpartum, 2011.  
**NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.** TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

**SUGAR URINE - FASTING**

SUGAR URINE - FASTING

NOT DETECTED

NOT DETECTED

**PHYSICAL EXAMINATION, URINE**

COLOR

AMBER

APPEARANCE

CLEAR



Scan to View Details

Page 9 Of 16



Scan to View Report

CIN : U85190MH2006PTC161480

(Refer to "CONDITIONS OF REPORTING" Overleaf)





Patient Ref. No. 66600003704552

CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS :

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 14/03/2023 08:04

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

## CHEMICAL EXAMINATION, URINE

PH	6.5	4.8 - 7.4
SPECIFIC GRAVITY	1.020	1.015 - 1.030
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

## MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
WBC	3-5	0-5	/HPF
EPITHELIAL CELLS	10-15	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	




Scan to View Details

Page 10 Of 16



Scan to View Report





Patient Ref. No. 66600003704552

CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS :

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 14/03/2023 08:04

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

**Interpretation(s)**

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

**GLUCOSE FASTING, FLUORIDE PLASMA**

GLUCOSE, FASTING, PLASMA

97

Diabetes Mellitus : > or = 126. mg/dL  
 Impaired fasting Glucose/  
 Prediabetes : 101 - 125.  
 Hypoglycemia : < 55.

METHOD : HEXOKINASE

PHYSICAL EXAMINATION, STOOL

RESULT PENDING

CHEMICAL EXAMINATION, STOOL

RESULT PENDING



Scan to View Details


Page 11 Of 16



Scan to View Report

CIN : U85190MH2006PTC161480

(Refer to " CONDITIONS OF REPORTING " Overleaf)



Patient Ref. No. 66600003704552

**CLIENT CODE :** CA00010147 - MEDIWHEEL  
**CLIENT'S NAME AND ADDRESS :** MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

**PATIENT NAME :** MRS. BILALO ABRAHAM**PATIENT ID :** BILAF1103764126**ACCESSION NO :** 4126WC003808 **AGE :** 47 Years **SEX :** Female**ABHA NO :****DRAWN :****RECEIVED :** 11/03/2023 11:12**REPORTED :** 14/03/2023 08:04**REFERRING DOCTOR :** DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED**CLIENT PATIENT ID :**

Test Report Status	Results	Units
Preliminary		

**MICROSCOPIC EXAMINATION, STOOL**

RESULT PENDING



# DDRC SRL

## Diagnostic Services




Scan to View Details

Page 12 Of 16



Scan to View Report





Patient Ref. No. 66600003704552

**CLIENT CODE :** CA00010147 - MEDIWHEEL  
**CLIENT'S NAME AND ADDRESS:**

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in
**PATIENT NAME :** MRS. BILALO ABRAHAM**PATIENT ID :** BILAF1103764126**ACCESSION NO :** 4126WC003808 **AGE :** 47 Years **SEX :** Female**ABHA NO :****DRAWN :****RECEIVED :** 11/03/2023 11:12**REPORTED :** 14/03/2023 08:04**REFERRING DOCTOR :** DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED**CLIENT PATIENT ID :**

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

**Interpretation(s)**

Stool routine analysis is only a screening test for disorders of gastrointestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects & reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
pH	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

**ADDITIONAL STOOL TESTS :**

- Stool Culture:** - This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- Fecal Calprotectin:** It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test (FOBT):** This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- Clostridium Difficile Toxin Assay:** This test is strongly recommended in healthcare associated bloody or watery diarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL:** In patients of Diarrhoea, Dysentery, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay:** This test is recommended in severe gastroenteritis in infants & children associated with watery




Scan to View Details



Scan to View Report





Patient Ref. No. 66600003704552

**CLIENT CODE :** CA00010147 - MEDIWHEEL  
**CLIENT'S NAME AND ADDRESS:**

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@sri.in
**PATIENT NAME :** MRS. BILALO ABRAHAM**PATIENT ID :** BILAF1103764126**ACCESSION NO :** 4126WC003808 **AGE :** 47 Years **SEX :** Female**ABHA NO :****DRAWN :****RECEIVED :** 11/03/2023 11:12**REPORTED :** 14/03/2023 08:04**REFERRING DOCTOR :** DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED**CLIENT PATIENT ID :**

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

diarrhoea, vomiting & abdominal cramps. Adults are also affected. It is highly contagious in nature.

**Interpretation(s)**

**BLOOD UREA NITROGEN (BUN), SERUM-** Causes of increased levels include Pre renal (High protein diet, increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

**CREATININE, SERUM-** Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

**GLUCOSE, POST-PRANDIAL, PLASMA-** High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c GLYCOSYLATED HEMOGLOBIN (HbA1c), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as  $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

**HbA1c Estimation can get affected due to :**

- I. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
  - II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).
  - III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
  - IV. Interference of hemoglobinopathies in HbA1c estimation is seen in
    - a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
    - b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
    - c. HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
- TOTAL PROTEIN, SERUM-** Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease  
 Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

**URIC ACID, SERUM-** Causes of increased levels: -Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels - Low Zinc intake, OCP, Multiple Sclerosis

**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-**

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B, O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."



Scan to View Details

Page 14 Of 16



Scan to View Report

CIN : U85190MH2006PTC161480

(Refer to "CONDITIONS OF REPORTING" Overleaf)





CLIENT CODE : CA00010147 - MEDIWHEEL  
 CLIENT'S NAME AND ADDRESS: TUCARE LIMITED

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in

PATIENT NAME : MRS. BILALO ABRAHAM

PATIENT ID : BILAF1103764126

ACCESSION NO : 4126WC003808 AGE : 47 Years SEX : Female

ABHA NO :

DRAWN :

RECEIVED : 11/03/2023 11:12

REPORTED : 14/03/2023 08:04

REFERRING DOCTOR : DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

CLIENT PATIENT ID :

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

The test is performed by both forward as well as reverse grouping methods.

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia (>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

#### TEST INTERPRETATION

**Increase in:** Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

**Decreased in:** Polycythemia vera, Sickle cell anemia

#### LIMITATIONS

**False elevated ESR :** Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

**False Decreased :** Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

#### REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACCPress, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

SUGAR URINE - POST PRANDIAL-METHOD: DIPSTICK/BENEDICT'S TEST

CYTOLOGY - CS (PAP SMEAR)-METHOD: STAINING- MICROSCOPY

Specimens sent for biopsy will be preserved in the Lab only for 30 days after despatch of reports. They will be discarded after this period. Slides/blocks of tissues will be issued only on written request from the concerned medical officer. Slides / Blocks and Reports will be preserved only for a period of 10 years. Generally Slides will be made available only a day after giving the request. Only two copies of the report will be given. Additional copies will be given only on production of a letter from the concerned doctor. Special stains & tests will be done wherever necessary to assist diagnosis and will be charged extra.

SUGAR URINE - FASTING-METHOD: DIPSTICK/BENEDICT'S TEST

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

#### Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

#### Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g., galactosemia), Drugs- insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

**NOTE:** While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.




Scan to View Details



Scan to View Report





Patient Ref. No. 66600003704552

**CLIENT CODE :** CA00010147 - MEDIWHEEL  
**CLIENT'S NAME AND ADDRESS :**

 MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED  
 F701A, LADO SARAI, NEW DELHI,  
 SOUTH DELHI, DELHI,  
 SOUTH DELHI 110030  
 DELHI INDIA  
 8800465156

 DDRC SRL DIAGNOSTICS  
 DDRC SRL Tower, G-131, Panampilly Nagar,  
 PANAMPALLY NAGAR, 682036  
 KERALA, INDIA  
 Tel : 93334 93334  
 Email : customercare.ddrc@srl.in
**PATIENT NAME :** MRS. BILALO ABRAHAM**PATIENT ID :** BILAF1103764126**ACCESSION NO :** 4126WC003808 **AGE :** 47 Years **SEX :** Female**ABHA NO :****DRAWN :****RECEIVED :** 11/03/2023 11:12**REPORTED :** 14/03/2023 08:04**REFERRING DOCTOR :** DR. MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED**CLIENT PATIENT ID :**

Test Report Status	Preliminary	Results	Units
--------------------	-------------	---------	-------

**MEDIWHEEL HEALTH CHECKUP ABOVE 40(F)TMT****ECG WITH REPORT****REPORT**

TEST COMPLETED

**MAMMOGRAPHY -BOTH****REPORT**

TEST COMPLETED

**USG ABDOMEN AND PELVIS****REPORT**

TEST COMPLETED

**CHEST X-RAY WITH REPORT****REPORT**

TEST COMPLETED

**\*\*End Of Report\*\***Please visit [www.srlworld.com](http://www.srlworld.com) for related Test Information for this accession

**DR.HARI SHANKAR, MBBS MD**  
 (Reg No - TCMC:62092)  
 HEAD - Biochemistry &  
 Immunology

**DR.VIJAY K N, MBBS MD(PATH)**  
 (Reg No - KMC:91816)  
 HEAD-HAEMATOLOGY &  
 CLINICAL PATHOLOGY

**DR.SMITHA PAULSON, MD**  
 (PATH),DPB  
 (Reg No - TCMC:35960)  
 LAB DIRECTOR & HEAD-  
 HISTOPATHOLOGY &  
 CYTOLOGY

**DR.NISHA G, MBBS MD(PATH),**  
 (Reg No - TCMC:45399)  
 CONSULTANT PATHOLOGIST



Scan to View Details

Page 16 Of 16



Scan to View Report

CIN : U85190MH2006PTC161480

(Refer to "CONDITIONS OF REPORTING" Overleaf)

This is to certify that I have examined

MR / MS Bilalo Abraham .....aged 47.....and

his / her oral findings are as follows

D - Decay

M - Missing —

F - Filling —

<u>M</u>															
8	7	6	5	4	3	2	1	1	2	3	4	5	6	7	8
8	7	<u>6</u>	5	4	3	2	1	1	2	3	4	5	6	7	8
		<u>7</u>													

Oral hygiene status : Good / Fair / Poor

Calculus / Stains : —

Any other findings : —

Date : 11/3/23

  
Dr. K C Jose





Date..11.03.2023

**OPHTHALMOLOGY REPORT**

This is to certify that I have examined

Mr / Ms : ..... *Bilalo Abha hem* ..... Aged.....*47*.....and his / her

visual standards is as follows :

**Visual Acuity:**

For far vision

R: ..... *6/18* .....

*2PNC R 6/9  
L 6/9*

L: ..... *6/18* .....

For near vision

R: ..... *N6* .....

L: ..... *N6* .....

Color Vision : ..... *Normal* .....

.....



*Nannu Elizabeth*  
**Nannu Elizabeth**  
**(Optometrist)**



ID: 3808  
BILALO ABRAHAM  
Female 47Years


*Bilal*

11-03-2023 01:09:21 PM  
HR : 60 bpm  
P : 96 ms  
PR : 155 ms  
QRS : 86 ms  
QT/QTc : 407/410 ms  
P/QRST : 39/8/35  
RV5/SV1 : 1.783/1.126 mV

Diagnosis Information:

Within normal limits  
Dr. George Thomas MD, FCSI, FIAE  
Cardiologist

Technician : ALEENA  
Ref-Phys. : MEDIWHEEL  
Report Confirmed by:





NAME: MRS BILALO ABRAHAM	STUDY DATE 11/03/2023
AGE / SEX :47 YRS / F	REPORTING DATE :11/03/2023
REFERRED BY : MEDIWHEEL	ACC NO : 4126WC003808

**X - RAY - CHEST PA VIEW**

- Both the lung fields are clear.
- B/L hila and mediastinal shadows are normal.
- Cardiac silhouette appears normal.
- Cardio - thoracic ratio is normal.
- Bilateral CP angles and domes of diaphragm appear normal.

**IMPRESSION: NORMAL STUDY****Kindly correlate clinically****Dr. NAVNEET KAUR, MBBS,MD  
Consultant Radiologist.**



NAME	MRS BILALO ABRAHAM	AGE	47 YRS
SEX	FEMALE	DATE	March 11, 2023
REFERRAL	MEDIWHEEL ARCOFEMI	ACC NO	4126WC003808

### USG BOTH BREASTS

**Clinical details:** Screening

Real Time gray scale B mode imaging of breasts reveals:

#### RIGHT BREAST

- Prominent echogenic fibroglandular parenchyma is seen.
- Retroareolar region normal.
- Nipple and areola appears normal.
- Axillary tail normal.
- No evidence of any regional lymphadenopathy

#### LEFT BREAST

- Prominent echogenic fibroglandular parenchyma is seen.
- Retroareolar region normal.
- Nipple and areola appears normal.
- Axillary tail normal.
- No evidence of any regional lymphadenopathy

#### IMPRESSION:

- **Bilateral mild fibroadenosis (BIRADS II)**
- **No other significant abnormality detected.**


*Navneet*  
 Dr. NAVNEET KAUR MBBS . MD  
 Consultant Radiologist

**Thank you for referral. Your feedback will be appreciated.**



NOTE: This report is only a professional opinion based on the real time image finding and not a diagnosis by itself. It has to be correlated and interpreted with clinical and other investigation findings. Review scan is advised, If this ultrasound opinion and other clinical findings / reports don't correlate.







NAME	MRS BILALO ABRAHAM	AGE	47 YRS
SEX	FEMALE	DATE	March 11, 2023
REFERRAL	MEDIWHEEL ARCOFEMI	ACC NO	4126WC003808


**USG ABDOMEN AND PELVIS**

LIVER	Measures ~ 11.6 cm. Bright echotexture. Smooth margins and no obvious focal lesion within. No IHBR dilatation. Portal vein normal in caliber .
GB	Partially contracted.
SPLEEN	Measures ~ 10.3 cm, normal to visualized extent. Splenic vein normal.
PANCREAS	Normal to visualized extent. PD is not dilated.
KIDNEYS	RK: 9.5 x 3.3 cm, appears normal in size and echotexture. LK: 10.6 x 3.8 cm, appears normal in size and echotexture. No focal lesion / calculus within. Maintained corticomedullary differentiation and normal parenchymal thickness. No hydroureteronephrosis.
BLADDER	Normal wall caliber, no internal echoes/calculus within.
UTERUS	Anteverted, normal in size [ 8.2 x 3.2 x 5 cm] and echopattern. No focal lesion seen. ET - 6.1 mm.
OVARIES	RT OV: 2.5 x 1 x 2.2 cm [volume ~ 3.2 cc]. LT OV: 2.7 x 1.1 x 1.7 cm [volume ~ 2.8 cc].
NODES/FLUID	Nil to visualized extent.
BOWEL	Visualized bowel loops appear normal.
IMPRESSION	<p>✦ <b>Grade I fatty liver.</b></p> <p>Kindly correlate clinically.</p>


*Navneet*  
**Dr. NAVNEET KAUR MBBS . MD**  
 Consultant Radiologist

**Thank you for referral. Your feedback will be appreciated.**

NOTE: This report is only a professional opinion based on the real time image finding and not a diagnosis by itself. It has to be correlated and interpreted with clinical and other investigation findings. Review scan is advised, if this ultrasound opinion and other clinical findings / reports don't correlate.









# DDRC SRL DIAGNOSTIC SERVICE PVT LTD

# Test Report

**BILALO ABRAHAM (47 F)**

ID: WCC003808

Date: 11-Mar-23

Exec Time : 0 m 0 s

Stage Time : 0 m 48 s

HR: 74 bpm

Protocol: Bruce

Stage: Supine

Speed: 0 mph

Grade: 0 %

(THR: 147 bpm)

B.P: 120 / 90

ST Level (mm)    ST Slope (mV / s)

ST Level (mm)    ST Slope (mV / s)



Chart Speed: 25 mm/sec

Filter: 35 Hz

Mains Filt: ON

Amp: 10 mm

Iso = R - 60 ms

J = R + 60 ms

Post J = J + 60 ms

Schiller Spandan V 4.7

Linked Median



# DDRC SRL DIAGNOSTIC SERVICE PVT LTD

# Test Report

**BILALO ABRAHAM (47 F)**

ID: WCC003808

Date: 11-Mar-23

Exec Time : 0 m 0 s

Stage Time : 0 m 25 s **HR: 72 bpm**

Protocol: Bruce

Stage: Standing

Speed: 0 mph

Grade: 0 %

(THR: 147 bpm)

B.P: 120 / 90

ST Level (mm) ST Slope (mV/s)



I





II



III



aVR



aVL



aVF



ST Level (mm) ST Slope (mV/s)

V1



V2



V3



V4



V5



V6



aVL

Chart Speed: 25 mm/sec

Filter: 35 Hz

Mains Filt: ON

Amp: 10 mm

Iso = R - 60 ms

J = R + 60 ms

Post J = J + 60 ms

Schiller Spandan V 4.7

Linked Median



# DDRC SRL DIAGNOSTIC SERVICE PVT LTD

# Test Report

**BILALO ABRAHAM (47 F)**

ID: WCC003808

Date: 11-Mar-23

Exec Time : 2 m 54 s

Stage Time : 2 m 54 s

HR: 110 bpm

Protocol: Bruce

Stage: 1

Speed: 1.7 mph

Grade: 10 %

(THR: 147 bpm)

B.P: 120 / 90

ST Level (mm) ST Slope (mV/s)

ST Level (mm) ST Slope (mV/s)



Chart Speed: 25 mm/sec

Filter: 35 Hz

Mains Filt: ON

Amp: 10 mm

Iso = R - 60 ms

J = R + 60 ms

Post J = J + 60 ms

Schiller Spandan V 4.7

Linked Median



# DDRC SRL DIAGNOSTIC SERVICE PVT LTD

# Test Report

**BILALO ABRAHAM (47 F)**

ID: WCC003808

Date: 11-Mar-23

Exec Time : 5 m 54 s Stage Time : 2 m 54 s **HR: 131 bpm**

Protocol: Bruce

Stage: 2

Speed: 2.5 mph

Grade: 12 %

(THR: 147 bpm)

B.P: 130 / 90

ST Level (mm) ST Slope (mV/s)

ST Level (mm) ST Slope (mV/s)




Chart Speed: 25 mm/sec

Filter: 35 Hz

Mains Filt: ON

Amp: 10 mm

Iso = R - 60 ms J = R + 60 ms Post J = J + 60 ms

Schiller Spandan V 4.7

Linked Median



# DDRC SRL DIAGNOSTIC SERVICE PVT LTD

# Test Report

**BILALO ABRAHAM (47 F)**

ID: WCC003808

Date: 11-Mar-23

Exec Time : 6 m 56 s Stage Time : 0 m 56 s **HR: 150 bpm**

Protocol: Bruce

Stage: Peak Ex

Speed: 3.4 mph

Grade: 14 %

(THR: 147 bpm)

B.P: 140 / 90

ST Level (mm) ST Slope (mV/s)

ST Level (mm) ST Slope (mV/s)




Chart Speed: 25 mm/sec

Filter: 35 Hz

Mains Filtr: ON

Amp: 10 mm

Iso = R - 60 ms

J = R + 60 ms

Post J = J + 60 ms

Schiller Spandan V 4.7

Linked Median



BILALO ABRAHAM (47 F)

ID: WCC003808

Date: 11-Mar-23

Exec Time : 7 m 2 s

Stage Time : 0 m 54 s HR: 110 bpm

Protocol: Bruce

Stage: Recovery(1)

Speed: 1 mph

Grade: 0 %

(THR: 147 bpm)

B.P: 160 / 90

ST Level (mm) ST Slope (mV / s)

ST Level (mm) ST Slope (mV / s)




Chart Speed: 25 mm/sec  
Schiller Spandan V 4.7

Filter: 35 Hz

Mains Filt: ON

Amp: 10 mm

Iso = R - 60 ms

J = R + 60 ms

Post J = J + 60 ms

Linked Median



BILALO ABRAHAM (47 F)

ID: WCC003808

Date: 11-Mar-23

Exec Time : 7 m 2 s

Stage Time : 0 m 54 s HR: 89 bpm

Protocol: Bruce

Stage: Recovery(2)

Speed: 0 mph

Grade: 0 %

(THR: 147 bpm)

B.P: 150 / 90

ST Level (mm) ST Slope (mV / s)

ST Level (mm) ST Slope (mV / s)




Chart Speed: 25 mm/sec

Filter: 35 Hz

Mains Filt: ON

Amp: 10 mm

Iso = R - 60 ms

J = R + 60 ms

Post J = J + 60 ms

Schiller Spandan V 4.7

Linked Median



# DDRC SRL DIAGNOSTIC SERVICE PVT LTD

# Test Report

**BILALO ABRAHAM (47 F)**

ID: WCC003808

Date: 11-Mar-23

Exec Time : 7 m 2 s

Stage Time : 0 m 54 s **HR: 89 bpm**

Protocol: Bruce

Stage: Recovery(3)

Speed: 0 mph

Grade: 0 %

(THR: 147 bpm)

B.P: 150 / 90

ST Level (mm) ST Slope (mV / s)

ST Level (mm) ST Slope (mV / s)




Chart Speed: 25 mm/sec

Filter: 35 Hz

Mains Fil: ON

Amp: 10 mm

Iso = R - 60 ms

J = R + 60 ms

Post J = J + 60 ms

Schiller Spandan V 4.7

Linked Median



## DDRC SRL DIAGNOSTIC SERVICE PVT LTD

**Patient Details**      **Date:** 11-Mar-23      **Time:** 13:54:13  
**Name:** BILALO ABRAHAM    **ID:** WCC003808  
**Age:** 47 y      **Sex:** F      **Height:** -- cms      **Weight:** -- Kgs  
**Clinical History:** NIL


**Medications:**

### Test Details

**Protocol:** Bruce      **Pr.MHR:** 173 bpm      **THR:** 147 (85 % of Pr.MHR) bpm  
**Total Exec. Time:** 7 m 2 s      **Max. HR:** 149 ( 86% of Pr.MHR )bpm      **Max. Mets:** 10.20  
**Max. BP:** 160 / 90 mmHg      **Max. BP x HR:** 23840 mmHg/min      **Min. BP x HR:** 5760 mmHg/min  
**Test Termination Criteria:** Target HR attained

### Protocol Details

Stage Name	Stage Time (min : sec)	Mets	Speed (mph)	Grade (%)	Heart Rate (bpm)	Max. BP (mm/Hg)	Max. ST Level (mm)	Max. ST Slope (mV/s)
Supine	0 : 54	1.0	0	0	64	120 / 90	-0.64 aVR	2.83 III
Standing	0 : 31	1.0	0	0	73	120 / 90	-3.40 V3	-4.95 V2
1	3 : 0	4.6	1.7	10	109	120 / 90	-3.82 V6	-3.89 V6
2	3 : 0	7.0	2.5	12	131	130 / 90	-2.12 V5	2.48 II
Peak Ex	1 : 2	10.2	3.4	14	149	140 / 90	-1.27 III	3.54 V5
Recovery(1)	1 : 0	1.8	1	0	110	160 / 90	-1.27 III	3.18 V3
Recovery(2)	1 : 0	1.0	0	0	95	150 / 90	-0.85 aVR	2.83 II
Recovery(3)	0 : 41	1.0	0	0	84	140 / 90	-0.21 aVR	1.77 II





# DDRC SRL DIAGNOSTIC SERVICE PVT LTD

## Patient Details

Date: 11-Mar-23

Time: 13:54:13

Name: BILALO ABRAHAM ID: WCC003808

Age: 47 y

Sex: F


Height: -- cms

Weight: -- Kgs

## Interpretation

The patient exercised according to the Bruce protocol for 7 m 2 s achieving a work level of Max. METS : 10.20. Resting heart rate initially 64 bpm, rose to a max. heart rate of 149 ( 86% of Pr.MHR ) bpm. Resting blood Pressure 120 / 90 mmHg, rose to a maximum blood pressure of 160 / 90 mmHg.No Angina,No Arrhythmia.

No significant ST changes  
Test negative for inducible Ischemia

  
Dr. George Thomas MD,FCSI,FAE  
Cardiologist



Ref. Doctor: MEDIWHEEL

Doctor: -----

( Summary Report edited by user )